Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.920
-0.020 (-1.03%)
At close: May 12, 2025, 4:00 PM
2.050
+0.130 (6.77%)
After-hours: May 12, 2025, 5:47 PM EDT
Gain Therapeutics Employees
As of December 31, 2024, Gain Therapeutics had 25 total employees, including 23 full-time and 2 part-time employees. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
n/a
Profits / Employee
-$816,448
Market Cap
53.35M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GANX News
- 16 hours ago - Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 11 days ago - Gain Therapeutics to Participate at The Citizens Life Sciences Conference - GlobeNewsWire
- 12 days ago - Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - GlobeNewsWire
- 3 months ago - Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - GlobeNewsWire